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Introduction
Hodgkin lymphoma (HL) is a cancer of the lymphatic system characterized by the presence of Bcell derived Hodgkin Reed-Sternberg (HRS) tumor cells (1) . HL is relatively rare, but contributes substantially to worldwide disease burden, totalling 66,000 new cases in 2012 and 25,000 deaths (2) . It affects mainly young adults aged 15 to 35 years and older adults aged 55 years and over.
Classical HL (cHL) is the major form and comprises four histological subtypes of which the nodular sclerosis HL (NSHL) subtype is most common followed by mixed cellularity HL (MCHL).
In approximately one-third of cHL cases in industrialised countries, the HRS cells are a clonally expanded population of Epstein-Barr virus (EBV)-infected cells. Young adult and NSHL cases are less likely to be EBV-positive than older adult and MCHL cases (3); EBV-positive cases are more likely to be male in contrast to more equal gender representation among EBV-negative cases. EBVpositive cases are associated with recent EBV infection, as evidenced by an association with infectious mononucleosis, and also with weakened immunity, e.g. HIV infection or iatrogenic immunosuppression after organ transplantation (4-6). The human leukocyte antigen (HLA) genes, located within the major histocompatibility complex (MHC) region, have been implicated in the etiology of cHL (7) (8) (9) (10) (11) . Some associations show heterogeneity by tumor EBV status (9, (11) (12) (13) (14) reinforcing the importance of acknowledging EBV status in examining the etiology of cHL.
Here, we expanded our investigation of the MHC region based on data from a previous cHL genome-wide association study (GWAS) and performed EBV-status specific analyses using imputation procedures for both SNPs and HLA alleles.
Materials and Methods
Imputation of 791,716 SNPs in human chromosome 6 was conducted using MACH v1.0 (15) HL EBV status was ascertained through in situ hybridization for EBERs and/or through immunohistochemical staining for EBV LMP-1 protein on formalin-fixed paraffin-embedded tumor samples as described previously (11) .
Test of association between imputed SNPs and cHL as well as by subtypes (i.e. NSHL, MCHL, EBV-positive cHL, and EBV-negative cHL) was performed using a probabilistic dosage model in ProbABEL v0. 4.3 (17) , adjusted for sex and the first informative eight eigenvectors from a principal components analysis (EIGENSOFT 3.0, Broad Institute, Cambridge, MA) derived using a subseries of 11,029 SNPs across the genome to control for potential population stratification (18) .
Additionally, we adjusted for the effect of rs2734986 (HLA-A), rs6904029 (HCG9), rs2248462
(MICB), rs2395185 (HLA-DRA) and rs6903608 (HLA-DRA), five MHC region SNPs previously associated with cHL risk.
For the replication series, 468 cHL cases and 551 study-specific controls from EPILYMPH, SNLG, YHHCCS, and the Epidemiology and Genetics Lymphoma Case-Control Study had complete genotype data for the 6 MHC loci of interest (5 known loci and rs6457715) (Supplementary Table   S1 and S2). 106 of the EBV-typed cases were classified as EBV-positive cHL. Genotyping of rs6457715 was performed using Taqman Pre-Designed SNP Genotyping Assays (Applied Biosystems, Carlsbad, CA). The genotype distribution was in accordance with that expected by
Hardy-Weinberg equilibrium and the assay had duplicate genotyping concordance rate of >99%.
From the GWAS genotyped data, classical HLA loci A, C, B, DRB1, DRB3-5, DQA1, DQB1, and
DPB1 were imputed using HLA*IMP:02 (19) . We confirmed the robustness of the imputation process by comparing HLA loci imputation (except DRB3-5) with directly genotyped HLA data (locus-specific PCR followed by sequence specific oligonucleotide hybridization (20) ) in 334 UK and 284 Dutch individuals. The average concordance rate between HLA imputed and directly genotyped data was of 93.8% (ranging from 82.8% to 99.3%) (Supplementary Table S3 ).
LCLs were generated from blood samples from 95 healthy controls and 70 post-therapy cHL patients (from blood samples collected at least 1 year after completion of all therapies) by infection with EBV. Genotyping of the LCLs was carried out using a TaqMan SNP assay. Association between HLA-DPB1 gene expression levels and genotype was assessed by linear regression using R.
Results
We performed SNP imputation of 1,200 classical HL (cHL) cases and 5,726 control subjects of European origin to undertake a comprehensive evaluation of the MHC region in total cHL and by EBV tumor status of cHL, while controlling for the effects of previously described susceptibility variants (11). We did not identify any novel signal (P < 10 -7 ) in total cHL or the EBV-negative subgroup, in addition to previously described associations in MHC class I and class II regions (Supplementary Figure 1a and 1b) . However, three imputed genetic variants (rs6457715, rs6457714
and rs6457711) were associated with the EBV-positive subgroup at genome wide significance levels (P < 10 -7 ) (Figure 1 ). The rs6457715, rs6457714 and rs6457711 variants showed evidence of linkage disequilibrium (LD) and conditioning on rs6457715 (A/G) was consistent with a single association signal (risk allele frequencies: EBV-positive cHL=0.87; controls=0.79). We directly genotyped rs6457715 within a subset (N=562, methods) of the sample in which we undertook imputation, and the concordance rate for rs6457715 between categorized dosages and direct genotypes was 99.47%, confirming the high accuracy of the imputation process. Within this discovery set, the rs6457715 major allele (A) was strongly associated with an increased risk of Table   S2 ). The association was more pronounced in the model adjusted for known MHC cHL susceptibility variants in both the validation and replication cohorts (Supplementary Table S2 ). Figure 2 ) demonstrated a 2.3-fold increased risk of EBV-positive cHL associated with rs6457715 (allele A relative to allele G) (p=7.53x10 -12 ) but no effect within the EBV-negative subgroup (p=0.405) and marked evidence for heterogeneity between the EBV-positive and EBV-negative groups (p_het=3x10 -8 ). While the predominant cHL histological subtypes tend to be correlated with the tumor EBV status (NSHL and MCHL more likely to be EBV negative and positive, respectively (3)), the heterogeneity of this association remained when considering the tumor EBV status within the MCHL and NSHL histological subgroups, implying that EBV status is the main source of heterogeneity ( Figure 2 Modelling a genetic risk score of the three independent MHC alleles associated with EBVpositive cHL (rs2734986, rs6904029 (11)) and rs6457715) suggested that there was a per-allele increased odds of 1.86 for EBV positive cHL, with the highest quartile of allele carriers having a ~7
Combining the imputation-based GWAS and replication results (
fold increased odds relative to the lowest quartile (Supplementary Table S5 ).
Discussion
We have identified a novel group of highly correlated genetic variants, located near the MHC class-II HLA-DPB1 gene, which are associated with genetic susceptibility to cHL. Statistically robust observations were made in both discovery and validation cohorts, and cross validation of the genotyping methods confirmed their technical fidelity.
The association was restricted to the subgroup of cHL in which EBV was detected within the tumor cells by EBV EBER in-situ hybridization and/or LMP-1 immunohistochemistry. This implies that these alleles are only relevant to the subset of cHL that are "EBV positive cHL", i.e.
where the HRS cells appear originate from a clonally expanded population of EBV-infected cell.
Most MCHL cases are EBV positive, however as the heterogeneity by tumor EBV status was also observed following stratification by NSHL and MCHL subtypes of cHL. This strong heterogeneity implies a biological interaction between EBV and the genetic alleles leading to susceptibility to Hodgkin lymphoma irrespective of the histological subtype.
The association with the genetic variants was statistically independent of the previously described cHL susceptibility alleles found within the MHC region. A proportion of these other susceptibility alleles also demonstrate heterogeneity in their effects when considering the EBV status of the tumor (9, 11, 12) . The class I genetic variants rs2734986 and rs6904029, which correlated with HLA-A gene alleles A*02 and A*01 respectively, are associated with EBV-positive cHL, whereas a genetic variant located in the class II region, rs6903608 has been associated uniquely with EBV-negative cHL (9, 11, 12). As noted above for rs6457715, heterogeneity in EBV stratified cHL risk was observed even following stratification for the NSHL and MCHL subtypes, for the rs2734986 and rs6904029 and EBV positive cHL and rs6903608 and EBV negative cHL. All of these observations taken together imply a remarkable relationship between tumor EBV status and the risk conferred by genetic variants within the MHC region and reinforces the importance of acknowledging EBV status when examining the etiology of HL.
We were unable to establish a link between rs6457715 and a particular HLA allele (Supplementary   Table S4 ), albeit within the limitation inferring HLA genotypes by imputation. rs6457715 resides within an intronic region of the pseudogene HLA-DPB2 and is suggested to be an HLA-DPB1 expression quantitative trait locus (eQTL) (21) . However, multiple additional independent genetic variants at this locus, not associated with EBV-positive cHL, are also suggested to be HLA-DPB1
eQTLs (Supplementary Table S6 ), implying that differences in HLA-DPB1 expression levels are unlikely to clearly explain the association. Furthermore, we were unable to replicate this eQTL association with rs6457715 and HLA-DPB1. As with the rs6903608 effect on EBV-negative cHL (9), the functional mechanism through which the association with rs6457715 is mediated remains ambiguous. ). The arrow highlights the new EBV-positive associated variant rs6457715.
There are three SNPs (rs6457715, rs6457714, and rs6457711) exceeding the p-value threshold at the 33Mb position, although results of two (rs6457715 and rs6457714) appear overlapping.
Figure 2
Summary of results for rs6457715 and risk of Hodgkin lymphoma by cHL subgroups.
Results of analyses combining the GWAS and replication stages are shown for total cHL and by histology, tumor cell EBV status, age of onset, and study. EBV-positive cHL results are also shown stratified by study. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived using multiple logistic regression assuming a log-additive genetic model and adjusting for the 5 known MHC loci (i.e. rs2734986, rs2248462, rs2395185, rs6903608 and rs3823355), sex and eight principal components analysis eigenvectors (or country in the replication analysis). The risk allele is the major allele (A) of rs6457715. Combined GWAS and replication results were generated using inverse variance weighting meta-analysis.
a Study-specific results for EPILYMPH and UK Studies included GWAS and replication data, while results for SCALE and the Netherlands studies are those from the GWAS.
